Cyclosporine A nephrotoxicity: Downregulation of multidrug resistance associated protein 2 (MRP2) by upregulated miRNA133a

Jochen WU Fries1,2*, Joe Schankin1, Sandra Stefanikova1, Melanie von Brandenstein1, Reinhard Büttner1 and Heike Goebel1

1Department of Pathology, University Hospital of Cologne, Cologne, Germany
2Department of Urology, University Hospital of Cologne, Cologne, Germany

Abstract

Background: Multidrug resistance associated protein 2 (MRP2) is described as a transport protein for xenobiotics, such as cyclosporine A (CyA). We have shown in proteinuric diseases that miRNA133a downregulates MRP2 by binding to its 3’UTR region, inducible by endothelin-1 (ET-1) via the ETB-receptor. The mechanism of nephrotoxicity in CyA treatment is still elusive. In particular, co-morbidities/clinical parameters, the morphological extent of MRP2 damage and the involvement of miRNA133a as a potential mechanism leading to nephrotoxicity have not been investigated.

Aims: To analyze co-morbidities, and the role of ET-1 and miRNA133a in CyA renal toxicity.

Methods: The effect of ET-1 alone or in combination with CyA on MRP2 and miRNA133a levels was studied in human proximal tubular cell culture. Co-morbidities/clinical factors in 230 biopsies from 124 patients were analyzed. Immune histology and morphometry of MRP2 expression was performed in 36 CyA biopsies (tubular damage, arteriolar damage, no damage) and in controls (5 null biopsies, 5 probes of normal renal tissue from benign tumor resection). On those specimens, a qRT-PCR for the detection of mrp2 and miRNA133a levels was also investigated.

Results: No single clinical parameter was statistically found responsible for CyA nephrotoxicity. Morphometric analysis revealed an increasing degree of MRP2 loss, i.e., no CyA toxicity to arteriolar / combined arteriolar, and tubular toxicity which showed the maximum degree of damage. In human proximal tubular cell culture, the combination of ET-1 and CyA had a higher effect of MRP2 loss/miRNA133a upregulation than ET-1 alone. By qRT-PCR, CyA induced marked tubular damage by downregulating the mrp2 gene via the upregulation of miRNA133a. However, transcriptional levels for mrp2 in arteriolar damage were high.

Conclusion: Downregulation of MRP2 by miRNA133a is an important mechanism of CyA tubular nephrotoxicity. Urinary analysis as detection assay and treatment options by an ETB-receptor antagonist are discussed.

Introduction

Endothelin-1 (ET-1), a major mediator of cellular signaling in human renal proximal tubule cells [1,2], is associated with regulation of multidrug resistance associated proteins (MRPs 1-6) [3]. Their function of increased drug efflux causes the multiple drug resistant phenotype [4,5]. If disturbed, it leads to nephrotoxicity [6,7]. ET-1 acting via ETB-receptor (ETBR) but not via ETA-receptor (ETAR) is able to downregulate MRP2[3,8].

MicroRNAs (miRNAs), short, non-coding RNAs, play important roles in cell function and development. Loeser, et al. described in human proteinuric disease that ET-1 stimulation via ETBR results in an upregulation of miRNA133a. This miRNA downregulates the mrp2gene by interacting with its 3’UTR, causing loss of MRP2 protein expression at the tubular surface.

Xenobiotics such as Cyclosporine A (CyA) are transported by MRP2[9], which is normally present on the luminal surface of proximal tubules [7]. CyA activates ET-1 in the kidney [10] in renal proximal tubules [11,12] and upregulates ETBR [13]. Since CyA induces different types of nephrotoxicity (i.e., arteriolar, tubular, arteriolar and tubular), we investigated the effect of ET-1 vs ET-1 + CyA in cell culture, a morphometric analysis of immune histologic detection of MRP2 in biopsies with different types of CyA nephrotoxicity, and the levels of MRP2 and miRNA133a by qRT-PCR in those biopsies. We show that MRP2 loss is correlated with miRNA133a upregulation in tubular damage. Since urinary detection of miRNA133a is possible, a clinical study using urine analysis of this miRNA and treating patients with an ETB-receptor antagonist could be valuable to better control tubular CyA toxicity.

Materials and methods

Approval for the procurement of human material

Since human tissue was investigated, procedures were followed as outlined in accordance with ethical standards, formulated in the Helsinki Declaration 1975 (and revised in 1983), or the Declaration of Istanbul (for transplant biopsies) with pre-approval by the Ethics Committee at the University Hospital, Cologne (Cologne, Germany; reference number: 19-350; tumor tissue through Biosomasota protocol).

*Correspondence to: Jochen WU Fries, Department of Pathology, University Hospital of Cologne, Cologne, Germany, Tel: 492214786861; Fax: 492214786860; E-mail: jochen.fries@uni-koeln.de

Key words: cyclosporine nephrotoxicity, endothelin-1, miRNA133a, multidrug resistance associated protein 2

Received: May 05, 2020; Accepted: May 20, 2020; Published: May 23, 2020
Human tissues

Formalin-fixed and paraffinized human renal biopsies were selected from the archives of the Department of Pathology, University Hospital of Cologne, Germany. Histologic evaluation was based on independent analyses by two staff pathologists (HG and JWU) using Hematoxylin-Eosin-stained, paraffin-sections. The following sets of cases were used:

1. Human renal proximal tubule cell culture: Primary human renal proximal epithelial tubules cells (RPTECs) were purchased from Cambrex (CC-2553; CambrexBio Science). These were cultured with serum-free renal epithelial cell medium.

2. Human biopsies with Cyclosporin A toxicity: A biotipical classification according to BANFF 2007 was performed. A total of 230 biopsies from 124 patients over a period of four years (2008-2011; Department of Pathology, University Hospital of Cologne) were rescreened, of which 107 were studied further (Table 1). Per case, four periodic acid Schiff (PAS) stained sections were obtained with 1-2 sections each, of which the arterioles and tubules in five randomized fields were counted. Cross-sectioned tubules were preevaluated using vacuolization of all epithelial cells in each facial field, and the damage sub classified (i.e., no vacuolization: 0; one to four tubules with vacuolization: 1; four to ten tubules with vacuolization: 2; and more than 10 tubules with vacuolization: 3). The arteriolar damage is characterized by a hyalinosis, which is subdivided into subendothelial, transmural, and circular categories. The transmural and the circular damage is caused by CyA, and was classified following BANFF 2007 classification (aha: arteriolar hyaline thickening, aah0: no typical lesions of CNI arteriolopathy; aah1: replacement of degenerated smooth muscle cells by hyaline deposits present in only one arteriole, no circumferential involvement; aah2: replacement of degenerated smooth muscle cells by hyaline deposits present in more than one arteriole, but no circumferential involvement; aah3: replacement of degenerated smooth muscle cells by hyaline deposits present in more than one arteriole, and circumferential involvement, independent of the number of arterioles involved [14].

3. Control renal tissue as reference: Renal biopsies were taken from the renal transplant (so-called null biopsies; n=5) but with subsequent failure of allocation (Table 2). Five specimens from normal renal tissue resected in the context of a benign tumor (Oncocytoma) were also used as additional controls for ischemic damage (Table 3).

Table 1. Patients’ biopsies after kidney transplantation treated with Cyclosporine A used for miRNA and MRP2 analysis

| No. | Ref. No. | Age | Time after TX | Gender | Creatinine mg/dl | Prot. g/d | Reject. | Damage |
|-----|----------|-----|---------------|--------|-----------------|----------|---------|--------|
| 11# | 22       | 46  | 1.089         | m      | 3.4-4 mg/dl     | yes      | no      |        |
| 16# | 29       | 34  | 62            | m      | 1.3 mg/dl       | yes      | no      |        |
| 18# | 37       | 67  | 6.900         | m      | increasing      | yes      | no      |        |
| 20# | 39       | 57  | 4.680         | f      | 3.5 mg/dl       | yes      | no      |        |
| 26# | 41       | 60  | 60            | f      | 3.5 mg/dl       | yes      | no      |        |
| 49# | 101      | 52  | 2.520         | m      | 5 mg/dl         | no       | no      |        |
| 50# | 102      | 66  | 14            | m      | 4.8 mg/dl       | no       | no      |        |
| 51# | 103      | 45  | 10            | f      | 10 mg/dl        | yes      | no      |        |
| 55# | 105      | 38  | 9.999         | f      | 3.4 mg/dl       | no       | no      |        |
| 58# | 116      | 19  | 60            | m      | 3 mg/dl         | yes      | no      |        |
| 59# | 122      | 21  | 30            | m      | 3 mg/dl         | yes      | no      |        |
| 61# | 2        | 72  | 9.999         | f      | 11.4 mg/dl      | no       | tubular |        |
| 64# | 33       | 46  | 360           | f      | increase        | yes      | tubular |        |
| 65# | 34       | 70  | 360           | f      | 3.4-4 mg/dl     | no       | tubular |        |
| 67# | 36       | 73  | 360           | m      | 6 mg/dl         | yes      | tubular |        |
| 68# | 45       | 10  | 14            | m      | no function      | no       | tubular |        |
| 72# | 66       | 20  | 24            | f      | 6.2 mg/dl       | no       | tubular |        |
| 73# | 66       | 20  | 24            | f      | 7.5 mg/dl       | no       | tubular |        |
| 76# | 83       | 52  | 30            | m      | 3.6 mg/dl       | no       | tubular |        |
| 78# | 87       | 15  | 90            | f      | 3.8 mg/dl       | no       | tubular |        |
| 79# | 90       | 41  | 10            | f      | yes             | yes      | tubular |        |
| 81# | 105      | 69  | 20            | m      | 2.9 mg/dl       | yes      | tubular |        |
| 84# | 115      | 59  | 3,600         | f      | no              | no       | tubular |        |
| 86# | 120      | 73  | 15            | f      | no              | no       | tubular |        |
| 89# | 16       | 51  | 905           | m      | artiolar        | no       | artiolar|        |
| 91# | 20       | 79  | 2.896         | f      | 4.5 mg/dl       | no       | artiolar|        |
| 93# | 49       | 34  | 9.999         | m      | 1.0-1.5 mg/dl   | no       | artiolar|        |
| 94# | 50       | 62  | 9.999         | f      | no              | no       | artiolar|        |
| 95# | 53       | 72  | 60            | m      | no              | no       | artiolar|        |
| 96# | 55       | 73  | 3             | m      | 2.5-3.5 mg/dl   | no       | artiolar|        |
| 100#| 76       | 70  | 9.999         | m      | 4.1 mg/dl       | no       | artiolar|        |
| 102#| 91       | 67  | 9.999         | m      | 3.2 mg/dl       | yes      | artiolar|        |
| 105#| 98       | 49  | 14            | m      | yes             | yes      | artiolar|        |
| 107#| 117      | 62  | 9.999         | m      | 6 mg/dl         | no       | artiolar|        |

Note: Prot: Proteinuria; TX: Transplantation; Reject: Rejection

Neprilus Renal Dis, 2020 doi: 10.15761/NRD.1000166 Volume 5: 2 -12
Cell culture analysis of MRP2 and miRNA133a

RPTECs were grown to 80–90% confluence and treated with ET-1 (50 nM, Sigma, E7754), or ET-1 plus Cyclosporine A (Sandz Pharmaceuticals; 200 ng/mL) for 72 hours, washed with phosphate-buffered saline (PBS), and prepared for qRT-PCR/Western blotting. All treatment studies were done in triplicate. As controls, RPTECs were grown without fetal calf serum for 24 h.

Evaluation of human transplant biopsies after Cyclosporine A treatment

From human transplant biopsies after CyA treatment, all available clinical information was collected in the following three categories: clinical parameters, laboratory values, and medications (Table 4).

Immune histology for MRP2

From formalin-fixed, paraffinized archival tissue blocks of renal biopsies, 4µm thick sections were cut, mounted on glass slides, and dried for 45 min. at 60°C. For deparaffinization, slides were submersed in Xylol and subsequently washed for 3 min each at room temperature (RT) in alcohol baths with decreasing concentration. Antigen retrieval was achieved by exposing the section at 100°C in a 0.01 M sodium citrate buffer (pH16) for 20 min. After cooling to RT for 20 min in this buffer, sections were washed twice, and endogenous peroxidase was blocked using 3% hydrogen peroxide for 30 min. After a subsequent BSA block for 2hrs at RT, sections were incubated overnight at 4°C with the primary antibody against MRP2 (ABIN445913) diluted to 1:200. After washing twice, the secondary antibody labeled with Diamobenzidine was applied for two hours at RT using a Thermo Autostainer. The enzyme reaction was carried out adding chromogen for 10 min at RT, after which the sections were dehydrated using ascending alcohol concentrations and cover-slipped for inspections.

Morphometry of MRP2

After PAS evaluation, from all CyA pretreated cases the ones with at least 60 well preserved tubular cross-sections were selected, resulting in cases with CyA damage of the arteriolar (n=10), tubular type (n=13), combined arteriolar + tubular type damage (n=5), and 12 cases without identifiable CyA damage (Table 1). These were compared to 5 cases of normal renal tissue taken from explanted, but not transplanted donor kidneys (no allocation in time) (Table 2) as well as 5 cases of normal renal tissue resected in the course of a benign renal tumor (Oncocytoma; Table3). In all cases, tubules were classified according to four groups of MRP2 preservation (i.e., no MRP2 loss: 100%; less than 50% MRP2 loss: <50%; more than 50% MRP2 loss: >50%; complete MRP2 loss: 0%), and evaluated by ANOVA.

Mrp2 gene and microRNA 133a analyses

Renal biopsy cases from each of the afore mentioned groups (no CyA damage, arteriolar damage, tubular damage, so-called null biopsies; Table 1, all marked with #), and from the 10 control cases (i.e., five cases of so-called null biopsies, Table 5; five cases of normal renal tissue from tumor resection) were used for mRNA and microRNA analysis.

Western blot analysis

Nuclear extracts were isolated from endothelin treated and untreated RPTECs according to the manufacturer’s protocol [Nuclear extraction kit, Active motif] [15]. Protein content was assayed with the Bradford protein assay (Bio-Rad) with BSA as standard. Proteins (20 µg) were separated by 10% SDS-PAGE and transferred to a PVDF membrane (Carl Roth, Cat. No. T830.1). Membranes were incubated with specific antibodies against MRP-2 (Abcam, M2III-6; 1:500 in TBST for 16hrs at 4°C), and β-actin (Santa Cruz, sc-1616) followed by HRP-labeled secondary antibodies in conditions according to the manufacture’s instructions. The bands were visualized using enhanced chemiluminescence Plus reagents (Pierce, ECL, 32109) according to the manufacturer’s instructions and the highly sensitive Chemiluminescence-Diana II CCD (Bio Imaging) program.

Densitometry

For densitometrical analysis the LabImage 1D 2006 program was used according to the provided protocols [16]. Statistics: mean and standard deviation were calculated. Differences between matched groups were analyzed by t-test for paired variables. Values of p<0.05 were considered statistically significant (p<0.05, *p<0.01).

miRNA isolation from FFPE samples/ cell culture

For miRNA isolation of the FFPE samples, the miRNasy FFPE kit from Qiagen was employed according to the manufacturer’s instructions.

### Table 2. Control renal biopsies at time of transplantation (no allocation)

| Patient ID | Diagnosis                  | Age (years) | Gender |
|------------|----------------------------|-------------|--------|
| 1          | Null bx; Tx                | 24          | f      |
| 2          | Null bx; Tx                | 28          | f      |
| 3          | Null bx; Tx                | 30          | m      |
| 4          | Null bx; Tx                | 29          | m      |
| 5          | Null bx; Tx                | 64          | m      |

### Table 3. Control renal tissue from tumor resection specimens (Oncocytoma)

| Patient ID | Diagnosis                  | Age (years) | Gender |
|------------|----------------------------|-------------|--------|
| 1          | Normal kidney; tumor resection | 48          | f      |
| 2          | Normal kidney; tumor resection | 67          | f      |
| 3          | Normal kidney; tumor resection | 49          | m      |
| 4          | Normal kidney; tumor resection | 59          | m      |
| 5          | Normal kidney; tumor resection | 61          | m      |

### Table 4. Human transplant biopsies evaluated using the following three categories: clinical parameters, laboratory values, and medications

| Clinical Parameter | Lab Values | Medications          |
|--------------------|------------|----------------------|
| Age of patient     | Hypercholesterinemia | ACE-inhibitors       |
| Age of transplant  | Creatinine | Calcium-antagonist   |
| Gender             | Protein in urine | Diuretic             |
| Ntx Rejection      | Glucose in urine | Beta-blocker         |
| Damage by Cya toxicity | Total protein | Thyroxin             |
| Grading of damage  | Urea       | PTH                  |
| Body size          | LDH        | Antibiotics          |
| Body weight        | yGT        | Biophosphonate       |
| Blood pressure     | GOT        | Immunosuppressive drugs |
| Diabetes mellitus  | GPT        |                      |
| Adipositas         | Hemoglobin |                      |
| Erythrocyte no.    | MCHC       |                      |
| Erythrocyte sedimentation speed | CRP |                      |
| HbA1c              | CRP        |                      |
| Cyclosporine A levels | Tacrolimus levels | Sirolimus levels |
| LDH: Lactate dehydrogenase; Ygt: y glutamyl-transferase; GPT: Glutamic oxaloacetate transaminase; GPT: Glutamic pyruvate transaminase; MCHC: Mean corpuscular hemoglobin concentration; CRP: C-reactive protein

**References:**

Fries JWU (2020) Cyclosporine A nephrotoxicity: Downregulation of multidrug resistance associated protein 2 (MRP2) by upregulated miRNA133a

**DOI:** 10.15761/NRD.1000166

---

**Nephrol Renal Dis, 2020**

Volume 5: 3 - 12
### Table 5. Result of evaluation of parameters from table 4

| Parameter                        | NO | YES |
|----------------------------------|----|-----|
|                                  | mean +/- STD | No. | mean +/- STD | No. |
| **Age**                          | 49 | 16  | 55 | 16 |
| **time period of NTx**           | 808 | 1794 | 869 | 1589 |
| **Gender**                       |     |     |     |     |
| female                           | 16 |     | 22 |     |
| male                             | 44 |     | 42 |     |
| **tx rejection**                 |     |     |     |     |
| No                               | 37 |     | 45 |     |
| Yes                              | 23 |     | 19 |     |
| **type of damage**               |     |     |     |     |
| No damage                        | 60 |     | 0  |     |
| arteriolar damage                | 0  |     | 22 |     |
| tubular damage                   | 0  |     | 27 |     |
| Combined damage                  | 0  |     | 15 |     |
| **BL (cm)**                      | 175 | 9  | 171 | 10 |
| **BW (kg)**                      | 81 | 15 | 75 | 14 |
| **RRSys**                        | 134 | 22 | 129 | 23 |
| **RR (mmHg)**                    | 77 | 14 | 75 | 16 |
| **RR (no medicine; sys)**        | 139 | 26 | 136 | 25 |
| **RR (treated)**                 | 82 | 15 | 79 | 17 |
| **Diabetes**                     |     |     |     |     |
| no                               | 50 |     | 52 |     |
| yes                              | 10 |     | 12 |     |
| **Adipositas (BMI>30)**          |     |     |     |     |
| no                               | 54 |     | 57 |     |
| yes                              | 6  |     | 7  |     |
| **Hypercholesterolemia (>200mg/ dl)** |     |     |     |     |
| no                               | 46 |     | 49 |     |
| yes                              | 14 |     | 15 |     |
| **Creatinine (0.5- 1.1 mg/dl)**  | 2.25 | 1.57 | 2.57 | 2.03 |
| **Glucose in urine**             |     |     |     |     |
| negative                         | 25 |     | 30 |     |
| positive                         | 3  |     | 3  |     |
| **Erythrocytes in urine**        |     |     |     |     |
| negative                         | 14 |     | 21 |     |
| positive                         | 14 |     | 11 |     |
| **Protein in urine**             |     |     |     |     |
| negative                         | 7  |     | 13 |     |
| positive                         | 19 |     | 19 |     |
| **Urea (<50ml)**                 | 100 | 65 | 117 | 75 |
| **LDH (<250)**                   | 226 | 101 | 250 | 89 |
| **GOT (<50)**                    | 28 | 28 | 32 | 39 |
| **GPT (<50)**                    | 30 | 36 | 27 | 25 |
| **γGT (<60)**                    | 83 | 121 | 65 | 87 |
| **Hb (13.5-18)**                 | 10 | 2 | 10 | 2 |
| **MCHC (31- 37)**                | 32 | 4 | 32 | 3 |
| **Erythrocytes (4.5- 5.9)**      | 4 | 1 | 4 | 5 |
| **HbA1c (4.8- 6.0)**             | 6 | 1 | 6 | 1 |
| **CRP (<5.0 mg/l)**              | 23 | 24 | 24 | 31 |
| **Erythrocyte sedimentation speed (<14 ml/h)** | 28 | 25 | 32 | 28 |
| **Tacrolimus (µg/l)**            | 377 | 1886 | 9 | 7 |
| **Cyclosporine A**               | 183 | 74 | 140 | 94 |
| **Sirolimus**                    | . | . | 6 | 3 |
| **ACE inhibitor**                |     |     |     |     |
| no                               | 43 |     | 43 |     |
| yes                              | 17 |     | 21 |     |
| **Ca-antagonist**                |     |     |     |     |
| no                               | 42 |     | 52 |     |
| yes                              | 18 |     | 12 |     |
| **Diuretic**                     |     |     |     |     |
| no                               | 47 |     | 50 |     |
| yes                              | 13 |     | 14 |     |
| **ß-blocker**                    |     |     |     |     |
| no                               | 30 |     | 37 |     |
| yes                              | 30 |     | 27 |     |
| **Thyroxin**                     |     |     |     |     |
| no                               | 45 |     | 49 |     |
| yes                              | 0  |     | 0  |     |
| **PTH**                          |     |     |     |     |
| no                               | 45 |     | 49 |     |
| yes                              | 0  |     | 0  |     |
| **EPO**                          |     |     |     |     |
| no                               | 49 |     | 57 |     |
| yes                              | 11 |     | 7  |     |
protocol. RNA quantification was accomplished using the NanoDrop technology. miRNA from cell culture experiments was isolated with the PureLink miRNA isolation kit from Invitrogen according to the manufacturer’s protocol. miRNA was quantified using the NanoDrop technology [16].

RT-PCR for miRNA

The cDNA was obtained from 100 ng template RNA using the miScript II RT kit from Qiagen using 5x High Spec buffer. In order to be in the semi-quantitative range, the amount of cDNA was previously determined by titration and the number of PCR cycles was standardized. The RT-PCR was performed at 37 °C for 60 minutes followed by 95 °C for 5 minutes according to the manufacturer’s protocol. The PCR reactions were performed in a final volume of 25 µl. For analysis of the PCR product 2.5% agarose gels were performed and were run in 1× TAE buffer [15].

Quantitative real-time PCR (qRT-PCR) for miRNA

1 µl of the aforementioned cDNA was employed for real-time PCR analysis. The primers used were: miRNA 133a, forward: UUUGGUCCCCUCAACCACGUG, temp 50°C; 5s rRNA forward: GAUUUGAAGCCACCGUUG, temp 50°C. The MystiQ Universal PCR Primer (Sigma-Aldrich) served as a reverse universal primer. The primer for 5s ribosomal RNA was employed to normalize results among different samples for miRNA evaluation. The experimental settings were as described previously. All experiments were done in triplicates; 55 PCR cycles. Relative fluorescence was calculated using the ΔΔCT method as outlined in User Bulletin 2 (PE Applied Biosystems) [15]. Control biopsies for the CyA study (six cases of normal renal tissue from tumor resection specimens; Table 5) were used to calculate the ddct–values.

Statistics

To compare clinical data sets, these were transferred into the IBM SSS Statistics program, and analyzed for mean and standard deviation; plus subjected to a Levene’s test (variance homogeneity), a t-test, and a Pearson’s Chi-square test, respectively. Graphpad Prism 5.0 (Graph-Pad Software, La Jolla, USA) was used for statistics of qRT-PCR analyses in triplicates at different time points, assessed by the Bonferroni method based on one-way analysis of variance (ANOVA). Morphometric data was performed in triplicates. Differences were calculated by the Newman-Keuls method (*p<0.05, **p<0.01, ***p<0.001). All unmarked results were not statistically significant. Differences between groups were analyzed by unpaired t-test.

Results

Detection of MRP-2 and miRNA133a in cultured RPTECs

In comparison to control cells, MRP-2 was downregulated by 40% after ET-1 treatment for 72 hrs. Combined with CyA, ET-1 reduced the MRP-2 to 50% of the control level (Figure 1A). The qRT-PCR analysis for miRNA133a showed a clear increase in miR133a levels versus controls (used as calculation reference), the value being doubled after the combined treatment of ET-1 with CyA (Figure 1B).

Cyclosporin A cytotoxicity: MRP2 vs. miRNA133a expression

a. Classification of CyA treated renal transplant cases used and their clinical data: Reevaluating routinely diagnosed renal biopsies treated with CyA enabled the establishment of four major groups according to the BANFF 2007 classification (Table 1): i.e., no damage, arteriolar damage, tubular damage, and combined arteriolar plus tubular damage. Subsequently, the clinical data of three categories (i.e. clinical parameters, laboratory values, and medications) were collected and statistically analyzed (Table 4). This evaluation (Table 5) showed that the age variant in all groups was not statistically different (F=0.01,2,80=2.39; F=0.02). However, in all groups the levels of CyA were elevated despite of strict blood level control. Furthermore, the erythrocyte counts were low (on average 4x10¹⁰; norm 4.5x10⁶–5x10⁶).

The control group being subjected to CyA treatment without observed damage was characterized by younger patients with lower creatinine values, where a rejection was assumed. In contrast, patients belonging to the group with tubular damage, the diagnoses were confirmed within 24 d, having the highest creatinine values of all groups, on average about 6 mg/dl. Also, CyA values were higher than in the other groups (on average 194 mg/dl). In patients with an arteriolar damage, transplantation was caused by different renal comorbidities such as a chronic glomerulonephritis, ADPKD, or tumor infiltration. Functionally, they displayed the highest creatinine (above 3.2 mg/dl) and urea levels of all groups. However, the diagnosis was reached at a late stage after transplantation (mean 720 d). The group having arteriolar and tubular damage had no distinct clinical characteristics. Comparing all groups regarding statistical significance of potentially predicting values for CyA toxicity, analysis of the t-test did not yield a p-value below 0.05 for any of the clinical or medication parameters or for the laboratory values observed (Table 6). The frequency distribution measured by Pearson’s χ² testing was not below 0.05; thus, the null hypothesis had to be rejected (Table 7).

Morphologically observed changes

The analysis of CyA damage regarding proximal tubules showed by routine H&E staining typical hydropic swelling with loss of brush border. This so-called osmotic nephrosis (Figure 2A), however, was observed in different degrees, varying from nephron to nephron in a biopsy. Focally, there was a nest-like accumulation of tubules with such changes, while in other locations only individual cells were damaged (Figure 2A). Importantly, maintained brush border did not always show MRP2 expression by immune histology (Figure 2B; black arrow). On the other hand, a tubule could show a hydropically swollen tubular cells

| Biophosphonate | no | 45 | 49 |
|---------------|----|----|----|
| yes           | 0  | 0  | 0  |
| Antibiotics   | no | 45 | 49 |
| yes           | 0  | 0  | 0  |
| Immuno-suppressives | Tacrolimus | 28 | 23 |
|                | CyA | 17 | 19 |
|                | Sirolimus | 0  | 0  |
|                | both | 2  | 4  |

LDH: Lactate dehydrogenase; γ GT: γ glutamyl-transferase; GOT: Glutamic oxaloacetate transaminase; GPT: Glutamic pyruvate transaminase; MCHC: Mean corpuscular hemoglobin concentration; CRP: C-reactive protein

Fries JWU (2020) Cyclosporine A nephrotoxicity: Downregulation of multidrug resistance associated protein 2 (MRP2) by upregulated miRNA133a
doi: 10.15761/NRD.1000166
Table 6. Statistical analysis of parameters

| LEVENE Test | F | sig | t | df | Sig (2 sides) | mean diff. | std | std error diff. | lower | upper |
|-------------|---|-----|---|----|-------------|-----------|-----|-----------------|-------|-------|
| Age         | No | 0.646 | 0.423 | -1.922 | 122 | -121.238 | 0.057 | -5.654 | 2.942 | -11.478 | 0.189 |
| Transplantation Survival (d) | No | 0.172 | 0.679 | -0.179 | 90 | 98.007 | 0.859 | -60.239 | 36.597 | -72.721 | 60.563 |
| Gender      | No | 3.347 | 0.068 | 0.926 | 122 | 121.996 | 0.356 | 0.077 | 0.083 | -0.088 | 0.242 |
| Rejection damage | No | 3.881 | 0.051 | 1.013 | 101 | 120.047 | 0.313 | 0.086 | 0.086 | 0.086 | 0.086 |
| body length (cm) | No | 0.40 | 0.843 | 1.152 | 64 | 59.385 | 0.135 | 3.689 | 2.440 | -1.185 | 8.563 |
| Body weight (kg) | No | 0.052 | 0.820 | 1.658 | 71 | 70.937 | 0.102 | 5.754 | 3.471 | -1.168 | 12.676 |
| RR Sys (mmHg) | No | 0.532 | 0.473 | 0.401 | 23 | 22.900 | 0.692 | 2.378 | 1.937 | -0.832 | 14.588 |
| RR under Meds | No | 0.003 | 0.929 | 0.547 | 53 | 52.727 | 0.587 | 3.718 | 7.694 | -9.910 | 17.345 |
| DM           | No | 0.364 | 0.547 | -0.301 | 122 | 121.954 | 0.764 | -0.021 | 0.069 | -0.158 | 0.110 |
| Adipostasis (BMI >30) | No | 0.114 | 0.736 | -0.169 | 122 | 121.917 | 0.866 | -0.009 | 0.055 | -0.119 | 0.100 |
| Hypercolest. (>200mg/dl) | No | 0.001 | 0.978 | -0.014 | 122 | 121.51 | 0.989 | -0.001 | 0.077 | -0.153 | 0.151 |
| Creatinine (0.5-1.1 mg/dl) | No | 3.018 | 0.086 | -0.913 | 107 | 102.992 | 0.384 | -0.31896 | -0.34053 | -1.0187 | 0.37395 |
| SistGlucose | No | 0.178 | 0.678 | 0.209 | 59 | 55.726 | 0.835 | 0.016 | 0.078 | -0.139 | 0.172 |
| SistErys   | No | 2.292 | 0.092 | 1.219 | 58 | 55.994 | 0.228 | 0.156 | 0.128 | 0.129 | 0.101 |
| Protein Stix | No | 4.668 | 0.035 | 1.084 | 1.085 | 55.288 | 0.283 | 0.137 | 0.28 | -0.116 | 0.301 |
| Harstoff (<50ml) | No | 2.694 | 0.104 | -1.120 | 90 | 89.165 | 0.266 | -16.475 | 14.707 | -45.694 | 12.744 |
| LDH (<250) | No | 0.228 | 0.638 | -1.127 | 82 | 81.613 | 0.262 | -23.677 | 21.012 | -65.477 | 18.122 |
| GOT (>50) | No | 1.062 | 0.308 | -0.615 | 92 | 80.674 | 0.540 | -4.285 | 6.967 | -18.122 | 9.551 |
| GPT (>50) | No | 0.209 | 0.649 | 0.499 | 93 | 83.611 | 0.619 | 3.172 | 6.302 | -9.463 | 15.807 |
| gGT (>60) | No | 2.143 | 0.147 | 0.759 | 86 | 81.758 | 0.450 | 17.234 | 22.721 | -27.933 | 62.401 |
| Hb (13.5-18) | No | 0.139 | 0.710 | 0.743 | 104 | 102.499 | 0.459 | 0.292 | 0.392 | 0.388 | 0.172 |
| MCHC (31-37) | No | 0.119 | 0.731 | 0.254 | 88 | 74.240 | 0.800 | 0.206 | 0.811 | -1.406 | 1.818 |
| Erythrocyten (4.5-5.9) | No | 1.430 | 0.235 | -0.737 | 97 | 95.752 | 0.463 | -0.493 | 0.670 | -1.822 | 0.836 |
| HbAlc (4.8-6.0) | No | 1.651 | 0.209 | -0.973 | 29 | 27.268 | 0.339 | -0.327 | 0.336 | -1.015 | 0.351 |
| CRP (<5.0 mg/l) | No | 1.580 | 0.215 | -0.169 | 50 | 47.061 | 0.867 | 1.286 | 7.623 | -16.597 | 14.025 |
| BSG (>14 ml/h) | No | 0.381 | 0.536 | -0.380 | 36 | 32.415 | 0.706 | -3.807 | 8.803 | -20.935 | 14.321 |
| Tacrolimus (ug/l) | No | 3.646 | 0.062 | 0.965 | 50 | 27.001 | 0.344 | 368.167 | 385.572 | 142.610 | 199.585 |
| Cyclospoline | No | 1.815 | 0.188 | 1.371 | 29 | 28.716 | 0.181 | 43.218 | 31.523 | -21.254 | 107.690 |
| ACE inhibitor | No | 1.157 | 0.284 | -0.537 | 122 | 121.927 | 0.592 | -0.049 | 0.83 | -0.210 | 0.120 |
| Ca-blocker | No | 8.525 | 0.004 | 1.463 | 122 | 116.180 | 0.146 | 0.113 | 0.077 | -0.040 | 0.265 |
| Diuretic | No | 0.003 | 0.954 | -0.028 | 122 | 121.530 | 0.978 | -0.028 | 0.075 | -0.150 | 0.146 |
### Table 7. Chi-Quadrat-Tests nach Pearson

|                      | χ²  | Df | Sig. |
|----------------------|-----|----|------|
| Gender               | 0.865 | 1 | 0.352 |
| Rejection            | 1033 | 1 | 0.309 |
| Diabetes mellitus    | 0.092 | 1 | 0.762 |
| Obesity              | 0.029 | 1 | 0.865 |
| Hypercholesterinemia | 0.000 | 1 | 0.969 |
| ACE inhibitors       | 0.292 | 1 | 0.589 |
| Ca-antagonists       | 2137 | 1 | 0.144 |
| Diuretics            | 0.001 | 1 | 0.379 |
| beta-Blockers        | 0.761 | 1 | 0.383 |
| EPO                  | 1365 | 1 | 0.243 |
| Immunosuppression    | 1257 | 1 | 0.533 |

LDH: Lactate dehydrogenase; Ygt: γ-glutamyltransferase; GOT: Glutamic oxaloacetate transaminase; GPT: Glutamic pyruvate transaminase; MCHC: Mean corpuscular hemoglobin concentration; CRP: C-reactive protein

**Figure 1A.** RPTEC in culture being ET-1/ET-1 + CyA pretreated. Left part of figure, MRP-2 levels by Western blot in control, unstimulated cells, after ET-1 stimulation and after a combined ET- and CyA stimulation. The right part of figure shows a densitometric analysis of the Western blot with a reduction of MRP2 to 60% by ET-1 alone and to 70% in combination with CyA treatment.

**Figure 1B.** qRT-PCR for miRNA133a with an 100% increase in the levels for miRNA133a after ET-1 pretreatment vs. controls (used for calculation) and a more than 200-fold increase after ET-1 plus CyA pretreatment

but still show a MRP2 positivity in the preserved brush border (Figure 2B; green arrow), indicating that the damage had not yet completely destroyed the cell. This high variation makes it very difficult to define the degree of brush border with MRP2 loss without quantification. Arteriolar damage was identified by nodular appearing hyalinosis of arteriolar vessel walls being disseminated and variable between individual arterioles with different degree of severity (data not shown).

**Morphologic evaluation MRP2 – expression after CyA treatment vs. controls**

To validate the number of tubules which could be used to analyze for brush border integrity, a PAS staining was obtained, and the respective number of tubules counted. The number of tubules from so-called null biopsies, and from the normal tissue obtained from tumor resection was on average 80. Repeating the analysis for MRP2, values were slightly lower for CyA-undamaged, combined arteriolar/tubular damaged und null-biopsies but still always above 60 (unpublished data).

To semi-quantitatively group the degree of MRP2 loss at the level of brush border, a graduation system was used consisting of four subdivisions of brush border preservation: i.e., 100%, >50%, <50% and 0%.

Using this grading system, in a total of 36 cases the expression of MRP2 was investigated by box plot analysis (Figure 3) followed by one-way ANOVA to determine the intra-versus intervariability of the number of tubules with MRP2 staining according to the individual damage group. As the F-values show (Table 5), there was a highly statistically significant difference at the p<0.01 level between the groups with different types of damage and the controls (normal renal tissue from benign tumor resection specimens). The highest degree of MRP2 loss was observed in the group tubular damage followed by the arteriolar damage. The group of combined arteriolar and tubular change did not exceed the ones observed in the arteriolar group alone; however, this was based on only 5 cases. Even in the group, which did not show obvious CyA damage, there was a distinct difference to the controls although the overall loss of MRP2 was expectedly less than in any other group.

The control group of so-called null biopsies from transplant kidneys without timely allocation were the least well preserved of all showing an overall high loss of stainable brush border, particularly with a mean of 44.7% in the group of <50% MRP2 staining. Since this result in comparison to the renal tissue from the resection specimens had to be considered a post-biopsy event, this group was not chosen as control (see miRNA133a levels).

**Levels of mrp2 gene and miRNA133a by qRT-PCR**

To obtain results of a qRT-PCR analysis of the mrp2 gene and miRNA133 the identical cases were used. Figure 4A shows a high amount of mrp2 cDNA being generated after arteriolar damage, while the amount was low in tubular damage, in non-detectable damaged tissue after CyA, and in all control cases (of renal tissue from resection). In Figure 4B, the levels of miRNA133a for arteriolar vs. tubular damage are reversed in comparison to the ones measuring MRP2. While there is only a relatively small amount of miRNA133a activated in arteriolar damage, the tubular damage shows an overall marked increase of miRNA133a. Again, cases without recognizable damage and all controls have minimal miRNA133a activation. The amount of miRNA133a from the null-biopsies is very low (data not shown), supporting the

Fries J.W.U. (2020) Cyclosporine A nephrotoxicity: Downregulation of multidrug resistance associated protein 2 (MRP2) by upregulated miRNA133a

| Beta-Blocker | Yes | No   | Yes | No   | Yes | No   | Yes | No   | Yes | No   | Yes | No   |
|--------------|-----|------|-----|------|-----|------|-----|------|-----|------|-----|------|
| EPO          | 5.582 | 0.020 | 1.165 | 1.157 | 122 | 0.246 | 0.078 | 0.078 | 0.090 | 0.090 | -0.100 | -0.100 |
| Immunosuppression | 0.832 | 0.364 | -1.116 | -1.114 | 87.118 | 0.268 | -0.185 | 0.165 | -0.513 | -0.514 | 0.145 | 0.145 |

Arteriolar damage was identified by nodular appearing hyalinosis of arteriolar vessel walls being disseminated and variable between individual arterioles with different degree of severity (data not shown).
interpretation that this did not represented an *in vivo* but a post-biopsy ischemia alteration. Thus, normal renal tissue from tumor resection specimens with overall well preserved MRP2 detectability was used as reference to calculate the ddct values in Figure 4A and B.

**Discussion**

The present publication describes the loss of detectability of MRP2 in cases with and without Cyclosporine A toxicity as well as in cell culture versus upregulated miRNA133a levels as pathogenetic mechanism.

MRP2 has been shown to transport toxins and carcinogens into the supernate from renal proximal tubular cells [17], among them cyclosporine A [18,19]. CyA has been widely used as an immunosuppressant since the 1980s and has yielded highly improved transplant survival [20]. However, in clinical practice it proved to have a small therapeutic window and leading to serious therapeutic side effects [21,22] necessitating so-called C2-monitoring [23,24]. To show the effect of ET-1 with/without the combination of CyA, we analyzed RPTECs in culture. By Western blot of MRP2 (Figure 1A) and by qRT-PCR of miRNA133a (Figure 1B) we demonstrated that MRP2 and the miRNA is inversely correlated. This is even more enhanced, if CyA is added as pretreatment. In agreement with our previous report in human proteinuric disease [25], we have again found that miRNA133a is an important regulator of MRP2 expression.

The damage caused by CyA can be observed inspite of strict therapeutic controls, leading to acute toxicity [26], which is then histologically typically characterized by an arteriolar (necrosis, hyalinosis) and/or tubular damage (isometric vacuolisation) [27]. Several months after transplantation and progressing as the lifetime of the transplant continues [28], chronic transplant nephropathy develops, and correlates in its severity with the lifetime of the transplant, affecting all three renal structures (i.e., glomeruli, vessels, and tubules). Besides the hyaline arteriolopathy [29], a streak-like interstitial fibrosis extending into the medullary rays, tubular atrophy (IFTA), and eggshell-like calcifications are observed [30]. We hypothesized that this distinct morphologic damage should be associated with characteristic clinical changes helping to identify patients at risk.

Thus, our analysis of different clinical parameters, laboratory values, and medications (Table 4) was targeted to detect one or more factors as being eye-catching and proving to be of exceptional value in the pathophysiological understanding of the development of the different degrees of damaged vs. undamaged transplant kidneys. However, in spite of collecting data from 124 patients with 230 biopsies (Table 1) of which 107 were evaluated with the parameters as listed in Table 4, statistical analysis did not yield any significant results but rather a tendential significance only (Tables 6 and 7). This may be due to the fact that this was based on results from a single center study that proved too small to be statistically significant, while to our knowledge, it was the first of such studies being done. To date, factors influencing the outcome of renal transplants have been the so-called cold ischemia time of more than 20 hours, the number of HLA mismatches [31] and the patients’ gender. We could confirm the negative influence of cold ischemia and the lifetime of the transplant as potentially causing more arteriolar damage. As an aggravating factor, we found that blood CyA levels were high despite being strictly controlled. Abnormal lab values such as high levels of urea were found, particularly in the group with arteriolar damage. Low erythrocyte counts were detected in all groups. From these investigations, it can be surmised that CyA damage seems to be due to the interplay of different factors and the duration of drug intake over time. However, tubular toxicity leading to renal dysfunction is expectantly one of the most serious side effects of CyA treatment.

Tubular toxicity is an easily noticeable damage identified by its isometric vacuolization [27] in renal biopsies (Figure 2A). Since König, et al. [9] and El-Sheikh, et al. [32] demonstrated that CyA directly inhibited MRP2, we analyzed the degree of MRP2 loss in human biopsies from patients pretreated with CyA. The intention was to find a correlation with the type of damage (arteriolar vs. tubular), and to define its degree by evaluating semi-quantitatively MRP2 expression in cross-sectioned tubules of renal biopsies (Figure 3) using 4 subcategories. Reasons which made this evaluation more difficult than anticipated were several: (i) the occurrence of loss of brush border in single, individual cells while others having an intact brush border in a cross section; a damage type, which is not readily visualised in its importance in routine diagnostics; (ii) an MRP2 loss of staining while the brush border is still recognizable by light microscopy, not being detected without immune histology (Figure 2A and B), and (iii) evaluating cross-sections of tubules, we counted all tubules without visible MRP2 staining as damaged. It is not possible, however, to differentiate in the individual case, whether this loss of staining is due to ischemia/autolysis or to miRNA133a induced downregulation. This could also cause an overestimation of the number of MRP2 losses, since supravitally changes immediately before fixation leading to blabbing and brush border loss are known to occur [33]. Thus, the damage inflicted by CyA does not only affect whole cross sections but also individual cells, which prevents an easy overall evaluation of the degree of tubular damage in routine diagnostics without morphometry.

**Figure 2A.** Light microscopic image of isometric vacuolization involving single cells versus the entire tubular circumference. H&E staining

**Figure 2B.** Immune histology of MRP2 staining. The black arrows show isometric vacuolization with loss of brush border and MRP staining. The green arrows indicate isometric vacuolization with preserved detection of a MRP2 positive brush border. Magnification in both 1:400
Figure 3. Morphometric analysis of MRP2 positive brush border in groups of patients with different degrees of CyA damage or without CyA damage. A: MRP$^+$=100%; B: MRP$^+$>50%; C: MRP$^+$<50%; D: MRP$^+$<0%. Patient group 1: no damage; Patient group 2: arteriolar damage; Patient group 3: combined arteriolar and tubular damage; Patient group 4: tubular damage; Patient group 5: null biopsies; Patient group 6: controls of normal renal tissue after benign tumor resection (Oncocytoma). Bar=median; x=mean value; lower and upper quartiles, and lower and upper extreme with whiskers are shown. black dots=statistical outliers

Figure 4A. Analysis of MRP2 in renal biopsies with CyA damage (arteriolar; tubular); no damage as controls. Values from normal renal tissue of tumor resection specimens served to calculate ddct values (*$p<0.05$, **$p<0.01$)

Figure 4B. qRT-PCR analysis of miRNA133a in renal biopsies with CyA damage (arteriolar; tubular); no damage as controls. Values from normal renal tissue of tumor resection specimens served to calculate ddct values (*$p<0.05$, **$p<0.01$)
Since CyA is considered a therapeutic option in steroid resistant nephrotic syndrome particularly in African children with focal-segmental sclerosis, and proteinuric renal disease may cause a downregulation of MR2 already, the combination may well lead to nephrotoxicity. However, renal dialysis for these children is not readily available, and the reported degree of CyA induced nephrotoxicity in those children is 10% to 11.7%, respectively. Thus, prevention/amelioration of toxic side effects of CyA is highly desirable.

Urinary ET-1 upregulation has also been reported after cyclosporine administration and was found to be increased in kidneys after 1 year of cyclosporine treatment. In the animal models of killifish and shark, the effect of tubulotoxicity was mediated by binding of ET-1 to the ETBR. In 2015, Loser et al. proposed a signaling mechanism in humans where ET-1 stimulation via ETBR leads to upregulation of miRNA133a. This miRNA binds to the 3' UTR of the mrp2 gene, preventing its translation and causing a loss of stainable MR2. As we have shown, this mechanism occurs in different forms of glomerulonephritis (minimal change disease, membranous nephropathy), and could be demonstrated in the Adriamycin mouse model of proteinuria. These results led us to investigate the relationship between MR2 and miRNA133a in nephrotoxicity, using CyA treated biopsies from transplant patients.

In the CyA group with arteriolar damage a marked loss of MR2 detection was found: a mean value of 34% of tubules with more than 50% of MR2 staining and 41% of those with less than 50% of detectable staining. At the transcriptional level for mrp2 there was a high response with an average of 60%, while the at the miRNA133a level, only a low level of transcription was identified. Thus, in arteriolar damaged kidneys the downregulation of MR2 seems to be predominantly caused by ischemia, while only a small increase in miRNA133a is found, indicating a direct downregulation.

This is in marked contrast to tubular damage. While the mean values of immune histologic MR2 staining are comparable to the segmental sclerosis, and proteinuric renal disease may cause a loss of stainable MR2, the result obtained from the so-called null biopsies vs. normal renal tissue from tumor resection specimens was clearly exposed to ischemic time and showed a good preservation with expectantly low miRNA133a levels as well. For this reason, we used these cases as reference to calculate the ddct values. Thus, the histologic analysis alone does not provide a reliable measure of ongoing molecular changes leading to the development of renal dysfunction, which seem detectable by measuring miRNA133a levels.

From the aforementioned results and our previous report about the detectability of miRNA133a in the urine of patients, downregulated MR2 transporter could be anticipated by levels of miRNA133a, as assay in the urine. This may help in guiding therapy by better anticipating renal failure, while an adjunct ETBR antagonism may allow a better tolerance of CyA therapy, preventing unnecessary renal failure. This has been suggested from in vitro experiments, where the toxicity of CyA on cells from proximal tubules such as LLC-PK1 and MDCK has been blocked by an ETBR but not an ETAR antagonist.
Using an ETBR antagonist may concomitantly help to avoid CyA mediated arteriopathy, in analogy to Zheng, et al. [38] who have demonstrated that CyA activates ETBR in vascular smooth muscle cells via MAPK and NF-kB. Furthermore, blocking the ETBR prevents microvascular damage of CyA to neocapillaries [39].

Conclusion
In summary (Figure 5), we know so far that CyA induced tubular damage is associated with increased ET-1 levels [10-12], transactivating signaling into proximal tubules via increased levels of ETB-receptor [13]. This leads to a detectable loss of the MRP2 expression at the brush border level. This is caused by a PKC mediated [8] upregulation of miRNA 133a binding to the 3’ UTR of mrp2 [25] and leads to increased levels of miRNA133a in the urine [25]. Blocking ETB-receptor [13] downregulates detectable miRNA133a levels [25]. Blocking ETB-receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule.

Acknowledgements
The authors declare no-financial competing interests.

We gratefully acknowledge the help in immune histology by Mrs. Uschi Zenz.

References
1. Gerstung M, Roth T, Diener HP, Licht C, Fries JW. (2007) Endothelin-1 induces NF-kappaB via two independent pathways in human renal tubular epithelial cells. Am J Nephrol 7: 294-300.
2. Ong AC, Jowett TP, Firth JD, Burton S, Karet FE, et al. (1995) An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int 48: 390-401.
3. Masereeuw R, Terlouw SA, van Aubel RA, Russell FG, Miller DS (2000) Endothelin B receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol Pharmacol 57: 59-67.
4. Choi YH, YuAM (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Drug Metab Rev 20: 398-407.
5. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, et al. (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the MRP2 gene a good model of the human intestinal mucosa? Pharm Res 14: 377-3794.
6. Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, et al. (2012) The UCSF–FDA TransPortal: a public drug transporter database. Clin Pharmacol Ther 92: 545-546.
7. Miller DS, Masereeuw R, Carnes M, Collins AB, Schneeberger EE, Pascual MA, et al. (2002) Cyclosporin C alpha regulates nuclear pri-microRNA 15a release as part of endothelin signaling. Biochim Biophys Acta 1813: 1793-1802.
8. von Brandenstein MG, Ngum Abety A, Depping R, Schafer E, Dienes HP, Fries JW (2011) Protein kinase C alpha regulates nuclear pri-microRNA 15a release as part of endothelin signaling. Biochim Biophys Acta 1813: 1793-1802.
9. von Brandenstein M, Depping R, Schafer E, Dienes HP, Fries JW (2011) Protein kinase C alpha regulates nuclear pri-microRNA 15a release as part of endothelin signaling. Biochim Biophys Acta 1813: 1793-1802.
10. Soléz K, Colvin RB, Racusen LC, Haas M, Sis B, et al. (2008) Banff07 classification of renal allograft pathology: updates and future directions. Am J Transplant 8: 1-8.
11. Papachristou E, Papadimitropoulos A, Kotsantis P, Goumenos DS, Katsoris PG, et al. (2010) Interaction of endothelin-1 and nitric oxide pathways in human tubular epithelial cells under the influence of cyclosporine-A CsA stimulates ET-1 and NO pathways in HK-2 cells. Ren Fail 32: 727-732.
12. Cheng C, Grill CH, Schmid-Kottas A, Gruenert A, Jehle PM (1998) Endothelin release by rabbit proximal tubule cells: Modulatory effects of cyclosporine A, tacrolimus, HGF and EGF. Kidney Int 54: 1626-1636.
13. Papachristou E, Papadimitropoulos A, Kotsantis P, Goumenos DS, Katsoris PG, et al. (2009) Cyclosporine induces endothelin-1 mRNA synthesis and nitric oxide production in human proximal tubular epithelial cell cultures. Ren Fail 31: 372-376.
14. Frassinetti C, Da Silva BG Jr, De Sousa BFA, Oliveira CCM, Kubrusly M, et al. (2005) Treatment of steroid-resistant nephrotic syndrome with cyclosporine: study of 17 cases and a literature review. J Nephrol 18: 711-720.

Nephrol Dialt Transplant, 2020 doi: 10.15761/NRD.1000166 Volume 5: 11 - 15
Benigni A, Bruzzi I, Mister M, Azzollini N, Gaspari F, et al. (1999) Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. *Kidney Int* 55: 674-685.

Zimmerhackl LB, Mesa H, Krämer F, Kölmel C, Wiegele G, et al. (1997) Tubular toxicity of cyclosporine A and the influence of endothelin-1 in renal cell culture models (LLC-PK1 and MDCK). *Pediatr Nephrol* 11: 778-783.

Zheng JP, Cheng Z, Jiang J, Ke Y, Liu Z (2015) Cyclosporin A upregulates ETB receptor in vascular smooth muscle via activation of mitogen-activating protein kinases and NF-κB pathways. *Toxicol Lett* 235: 1-7.

Wilasrusmee C, Ondocin P, Bruch D, Shah G, Kittur S, et al. (2003) Amelioration of cyclosporin A effect on microvasculature by endothelin inhibitor. *Surgery* 134: 384-389.